Burkitt lymphoma in Brazil is characterized by geographically distinct clinico-pathological features and lack of p53 mutations by E Queiroga et al.
BioMed Central
Page 1 of 1
(page number not for citation purposes)
Infectious Agents and Cancer
Open AccessPoster presentation
Burkitt lymphoma in Brazil is characterized by geographically 
distinct clinico-pathological features and lack of p53 mutations
E Queiroga1,2, G Gualco1, L Weiss3, D Dittmer4, I Araujo5, C Klumb6, 
W Harrington Jr*7, E Os and C Bacchi1,2
Address: 1Consultoria Patologia, Botucatu, São Paulo, Brazil, 2University of São Paulo Medical School, São Paulo, Brazil, 3Division of Pathology 
at the City of Hope National Medical Center, Duarte, California, USA, 4Department of Microbiology and Immunology, Lineberger Comprehensive 
Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA, 5Prof. Edgard Santos University Hospital, Salvador, Bahia, Brazil, 
6Instituto Nacional do Cancer, Rio de Janeiro, Brazil and 7University of Miami Miller School of Medicine and Sylvester Cancer Center, Fogarty 
International Center (AIDS and Tuberculosis Program), Miami, Florida, USA
* Corresponding author    
Burkitt lymphoma (BL) is a highly aggressive non-Hodg-
kin lymphoma with a consistent MYC translocation.
Epstein Barr virus (EBV) has been associated with BL at
different frequencies depending on the clinical variant
and geographic regions. This is a large-scale study of BL in
Brazil, including 234 patients from five geographic
regions that are widely disparate socioeonomically,
including both the pediatric (61.1%) and adult (37.6%)
populations. EBV was present in 52.5 percent of all BL
cases, varying from 28.6 percent in the South to 76.4 per-
cent in the North. Most of the cases were EBV type A. The
frequency was higher in the pediatric group and EBV asso-
ciation within this age range predominated in all regions
except the South. p53 protein expression was observed in
16.2 percent and only rare cases showed p63 expression.
BL in Brazil is regionally distinct, has a low incidence of
p53 over expression and a higher than expected associa-
tion with EBV in sporadic cases.
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